Clearmind Medicine Expanding IP Portfolio with New US Patent Application for Treatment of Depression
Clearmind Medicine Inc. (NASDAQ: CMND) has filed a patent application with the USPTO for a novel combination of its psychedelic compound MEAI and SciSparc's Cannamide™ for treating depression. This development highlights Clearmind's commitment to expanding its intellectual property portfolio, which currently comprises 24 patents across 14 families, with 9 granted in major jurisdictions. The new patent aims to enhance treatment efficacy and safety for mental health disorders. Additionally, it aligns with the company's goal to create innovative solutions for under-treated health issues, including alcohol use disorder and obesity. This latest application demonstrates Clearmind's focus on developing regulated therapeutic options that could address significant patient needs.
- Filed patent application for MEAI and Cannamide™ combination for depression treatment.
- Expands Clearmind's intellectual property portfolio to 24 patents across 14 families.
- Nine patents granted in major jurisdictions, enhancing market position.
- Focus on developing safer and more effective treatments for mental health disorders.
- Dependence on the patent approval process, which is uncertain.
- Potential risks associated with the commercialization of new compounds.
The application is for a novel psychedelic-based combination, of Clearmind's MEAI and SciSparc's Cannamide™
Tel Aviv, Israel / Vancouver, Canada, April 21, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND), (FSE: CWY) (“Clearmind” or “the company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announces the filing of a patent application seeking to protect its unique combination of MEAI and SciSparc's Palmitoylethanolamide (PEA) for the treatment of depression.
The company filed a provisional patent application with the United States Patent and Trademark Office (USPTO) as part of its ongoing collaboration with SciSparc Ltd. (Nasdaq: SPRC) ("SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat central nervous system disorders.
This patent is an addition to Clearmind's robust intellectual property portfolio that includes patents for MEAI as a binge behavior regulator, as an alcoholic beverage substitute and others.
The patent application refers to novel proprietary combinations of MEAI and SciSparc's Palmitoylethanolamide (PEA), the active ingredient of its proprietary CannAmide™. It demonstrates Clearmind’s corporate mission to broaden the therapeutic psychedelic toolbox for patients with mental health disorders who await treatments with increased efficacy and safety while reducing cost.
Clearmind has a broad IP footprint in the psychedelic space with 24 patents in 14 patent families, nine of which have been granted in major jurisdictions like the US, Europe, China, and India. The company has already filed patent applications for the combination of Clearmind's MEAI with SciSparc's PEA compound for treating alcohol use disorder, cocaine addiction, and obesity and its related metabolic disorders.
About Clearmind Medicine Inc.
Clearmind is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements.
The company’s intellectual portfolio currently consists of fourteen patent families. The company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.
Shares of Clearmind are listed for trading on Nasdaq and the Canadian Securities Exchange under the symbol "CMND" and the Frankfurt Stock Exchange under the symbol “CWY.”
For further information visit: https://www.clearmindmedicine.com or contact:
Investor Relations
invest@clearmindmedicine.com
Telephone: (604) 260-1566
General Inquiries
Info@Clearmindmedicine.com
www.Clearmindmedicine.com
About SciSparc Ltd. (Nasdaq: SPRC):
SciSparc Ltd. is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists. SciSparc’s focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company is currently engaged in the following drug development programs based on THC and/or non-psychoactive cannabidiol (CBD): SCI-110 for the treatment of Tourette Syndrome, for the treatment of Alzheimer's disease and agitation; SCI-160 for the treatment of pain; and SCI-210 for the treatment of autism spectrum disorder and status epilepticus.
FORWARD-LOOKING STATEMENTS:
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. In addition, we cannot assure that any patent will issue as a result of a pending patent application or, if issued, whether it will issue in a form that will be advantageous to us. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report on Form 20-F filed with the SEC on February 6, 2023. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible for the contents of third-party websites.
FAQ
What is Clearmind Medicine's latest patent application related to?
When did Clearmind Medicine file its patent application?
What is the significance of the patent for Clearmind Medicine?
How many patents does Clearmind currently have?
What other health issues does Clearmind target with its patents?
